Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight

DelveInsight's "Alport Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology as well as the Alport Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Alport Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alport Syndrome Market Forecast
https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Alport Syndrome Market Report:
• The Alport Syndrome market size was valued ~USD 20 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In December 2025, Bayer announced the launch of a Phase IIa clinical trial evaluating BAY 3401016, an investigational monoclonal antibody designed to inhibit Semaphorin 3A (Sema3A), a protein implicated in kidney damage progression in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient ASSESS study (NCT07211685) is a randomized, double-blind, placebo-controlled trial with a group-comparison and extension phase, aiming to assess the safety and efficacy of BAY 3401016 in adults with Alport Syndrome.
• In June 2025, ENYO Pharma, a clinical-stage biotech company specializing in FXR agonists for treating serious kidney disorders, has announced the successful progression of its Phase 2 ALPESTRIA-1 trial involving 26 patients with Alport syndrome. Topline results are expected in the fourth quarter of 2025. Simultaneously, ENYO has completed its Series C funding round with an additional €6 million investment from Vesalius Biocapital IV, raising the total to €32 million.
• In January 2024, ENYO Pharma announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application, allowing the company to begin a Phase 2 clinical study of Vonafexor, a highly selective FXR agonist, for the treatment of Alport Syndrome.
• The overall number of existing cases of Alport Syndrome across the seven major markets (7MM) was approximately 160,000 in 2023, with projections indicating a rise by 2034.
• In the United States, there were nearly 68,000 existing cases of Alport Syndrome in 2023.
• In 2023, gender-specific cases of Alport Syndrome in the US consisted of approximately 52% males and 48% females.
• In 2023, among the type-specific cases, approximately 11,500 cases were attributed to XLAS, which constituted 85% of the cases in the US.
• Key Alport Syndrome Companies: Eloxx Pharmaceuticals, Inc., Biogen, River 3 Renal Corp., Travere Therapeutics, Inc. , Chinook Therapeutics U.S., Inc., Bayer, and others
• Key Alport Syndrome Therapies: ELX-02, Bardoxolone Methyl, R3R01, Sparsentan, Atrasentan, Finerenone, and others
• In 2022, there were around 2,200 cases of Alport syndrome in the age group 2-11, nearly 1,900 cases in the age group 12-17, and almost 25,000 cases in the age group 18 and above across the 7 Major Markets (7MM).
• The Alport Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alport Syndrome pipeline products will significantly revolutionize the Alport Syndrome market dynamics.

Alport Syndrome Overview
Alport Syndrome is a genetic disorder characterized by kidney disease, hearing loss, and eye abnormalities. It primarily affects the glomeruli, the tiny blood vessels in the kidneys that filter wastes and excess fluids from the blood to form urine. This condition typically results from mutations in genes that encode proteins involved in the structure and function of the glomeruli and the inner ear.

Get a Free sample for the Alport Syndrome Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alport Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alport Syndrome Epidemiology Segmentation:
The Alport Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalent Cases of Alport Syndrome in the 7MM
• Total Diagnosed Prevalent Cases of Alport Syndrome in the 7MM
• Gender-specific Cases of Alport Syndrome in the 7MM
• Age-specific Cases of Alport Syndrome in the 7MM
• Type-specific Cases of Alport Syndrome in the 7MM

Download the report to understand which factors are driving Alport Syndrome epidemiology trends @ Alport Syndrome Epidemiology Forecast
https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alport Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alport Syndrome market or expected to get launched during the study period. The analysis covers Alport Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Alport Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alport Syndrome Therapies and Key Companies
• ELX-02: Eloxx Pharmaceuticals, Inc.
• Bardoxolone Methyl: Biogen
• R3R01: River 3 Renal Corp.
• Sparsentan: Travere Therapeutics, Inc.
• Atrasentan: Chinook Therapeutics U.S., Inc.
• Finerenone: Bayer

Discover more about therapies set to grab major Alport Syndrome market share @ Alport Syndrome Treatment Landscape
https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alport Syndrome Market Strengths
• With a deeper understanding of the genetic basis of Alport syndrome, personalized treatment strategies can be tailored to an individual's specific genetic profiles. ELX-02 is expected to garner the first mover advantage in Alport syndrome apart from being the first gene therapy with reduced frequency of administration (8 weeks).
• An increase in research and development has paved the way for discovering novel MoA therapies such as dual NOX inhibitor (setanaxib), semaphorin-3A blocker (BAY3401016), selective endothelin A receptor antagonist (atrasentan) amidst the usage of ACE/ARB inhibitors as standard of care.

Alport Syndrome Market Opportunities
• Genetic advances may open the way for personalized treatment tailored to the particular genetic profiles of individuals with Alport syndrome. Thus, there is a huge opportunity for precision medicine approaches.
• Patient advocacy groups such as the Alport Syndrome Foundation can play a pivotal role in shaping the landscape for Alport syndrome. This foundation directs the majority of its resources to research and research-related activities resulting in groundbreaking knowledge and clinical trials pertaining to Alport syndrome.

Scope of the Alport Syndrome Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Alport Syndrome Companies: Eloxx Pharmaceuticals, Inc., Biogen, River 3 Renal Corp., Travere Therapeutics, Inc. , Chinook Therapeutics U.S., Inc., Bayer, and others
• Key Alport Syndrome Therapies: ELX-02, Bardoxolone Methyl, R3R01, Sparsentan, Atrasentan, Finerenone, and others
• Alport Syndrome Therapeutic Assessment: Alport Syndrome current marketed and Alport Syndrome emerging therapies
• Alport Syndrome Market Dynamics: Alport Syndrome market drivers and Alport Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Alport Syndrome Unmet Needs, KOL's views, Analyst's views, Alport Syndrome Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.